Sociedad Americana de Hirudoterapia

Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative?.

Research article published in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2002)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportEnsayos clínicosLeyh et al. · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2002

Abstract

We report on the treatment failure of low molecular weight heparin (LMWH) for anticoagulation in a pregnant woman that underwent artificial mitral valve replacement 10 years prior to her pregnancy. Until she became pregnant warfarin was administered for anticoagulation, but due to the often mentioned increased risk for warfarin-induced maternal and fetal complications, at gestational week 5 the anticoagulation regimen was switched to subcutaneous application of low molecular weight heparin. At gestational week 24 our patient developed acute life-threatening pulmonary edema and hemodynamic instability due to acute mitral valve thrombosis and underwent emergency valve re-replacement with a biological porcine valve. She recovered uneventfully and gave birth to a healthy child at gestational week 35. In addition to our case presentation we review the sparse evidence in the literature regarding anticoagulation in pregnant women with mechanical heart valves and discuss the rational of different anticoagulation regimens with regards to maternal and fetal outcome. Special consideration is directed towards LMWH administration as an alternative to oral anticoagulation during pregnancy in women with mechanical heart valves.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal ArticleReview
Indexed MeSH termsAdultAnticoagulantsFemaleHeart Valve ProsthesisHeparin, Low-Molecular-WeightHumansMitral ValvePregnancyPregnancy Complications, HematologicThrombosisWarfarin

Resumen

Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative?.

Por qué esto importa para la hirudoterapia

This case report describes treatment failure of low-molecular-weight heparin for anticoagulation in a pregnant woman with a mechanical mitral valve prosthesis, who developed acute valve thrombosis at gestational week 24 requiring emergency valve re-replacement, and reviews anticoagulation options for pregnant women with mechanical heart valves. The abstract contains no mention of leeches, hirudin, or any leech-derived therapeutic. Therefore, this article has no defensible relevance to hirudotherapy or the leech secretome.

Citación

Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative?.

Leyh et al. · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2002

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.